Pending European Commission approval, AYVAKYT will become the first and only therapy for people living with ISM in Europe. "Indolent systemic mastocytosis is often characterized by severe symptoms ...

CAMBRIDGE, Mass., Sept. 25, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomicall ...

European regulators have recommended a licence for Blueprint Medicines’ Ayvakyt (avapritinib), for adults with stomach tumours with certain mutations. Blueprint specialises in drugs that tackle ...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis-- For the first time, the estimated 40,000 patients with ...

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses ...

CAMBRIDGE, Mass., March 3, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company's Type II ...

Blueprint Medicines Corporation BPMC announced that the European Medicines Agency (“EMA”) has validated its Type II variation marketing authorization application seeking approval for its lead ...

Blueprint Medicines Corp.’s cancer drug Ayvakyt (avapritinib) looks set to gain an expanded label in Europe, amid a flurry of decisions from the European Medicines Agency’s CHMP scientific committee.

Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance. PR Newswire . Wed, Oct 30, 2024, 7:00 AM 12 min read.

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ...

--Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT ® for the treatment of adult patients with indolent systemic mastocytosis with moderate to severe ...

AYVAKYT® (avapritinib) is a kinase inhibitor approved by the European Commission for the treatment of three indications: adults with indolent systemic mastocytosis (ISM), adults with aggressive ...